1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,000 | 0,067 | 11.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Alligator Bioscience Provides an Update on Mitazalimab | 216 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 10, 2026 / Alligator Bioscience (STO:ATORX)(Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs... ► Artikel lesen | |
| 30.03. | Notice of Annual General Meeting in Alligator Bioscience AB | 253 | ACCESS Newswire | The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. LUND, SE / ACCESS Newswire / March 30... ► Artikel lesen | |
| 27.03. | The Nomination Committee's Proposals Regarding the Board of Directors for the Annual General Meeting in Alligator Bioscience AB | 236 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 27, 2026 / Alligator Bioscience (STO:ATORX) - The Nomination Committee of Alligator Bioscience AB (publ) ("Alligator Bioscience") proposes re-election of Hans-Peter... ► Artikel lesen | |
| 26.03. | Alligator Bioscience Publishes Annual Report for 2025 | 236 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / March 26, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced that the Annual Report for 2025, as well as the company's Remuneration Report, has been... ► Artikel lesen | |
| ALLIGATOR BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 18.03. | New data from Investigator-Initiated Study Evaluating Alligator Bioscience's Mitazalimab to be Presented at AACR Annual Meeting 2026 | 118 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 18, 2026 / Alligator Bioscience (STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced that... ► Artikel lesen | |
| 10.03. | Alligator Bioscience Strengthens Intellectual Property Protection for Bispecific Antibody Platform | 375 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / March 10, 2026 / Alligator Bioscience (STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced that... ► Artikel lesen | |
| 02.03. | Alligator Bioscience Comments on Henlius Dosing First Patient in Phase 2/3 Breast Cancer Study of HLX22 | 664 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 2, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that the first patient has been dosed... ► Artikel lesen | |
| 27.02. | Exercise Price Determined for the Exercise of Warrants Series TO 14 in Alligator Bioscience AB | 488 | ACCESS Newswire | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 12.02. | Alligator Bioscience AB (publ) GAAP EPS of -SEK 0.66, revenue of SEK 46K | 1 | Seeking Alpha | ||
| 12.02. | Alligator Bioscience AB Reports Full Year Financial Results for 2025 and for Q4 2025 and Provides a Business Update | 391 | ACCESS Newswire | Rights issue completed: Approximately SEK 91 million (gross) raised in December, strengthening financial position with additional warrant upside in 2026.Mitazalimab validation: OPTIMIZE-1 biomarker... ► Artikel lesen | |
| 05.02. | Invitation to Alligator Bioscience's Earnings Call on 12 February 2026 | 346 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 5, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs... ► Artikel lesen | |
| 30.01. | Change in Number of Shares and Votes in Alligator Bioscience AB | 323 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / January 30, 2026 / Alligator Bioscience (STO:ATORX) - During January 2026, the number of shares and votes in Alligator Bioscience AB ("Alligator Bioscience") has increased... ► Artikel lesen | |
| 16.01. | New equity right for trading, Alligator Bioscience AB | 315 | GlobeNewswire | At the request of Alligator Bioscience AB, equity rights will be traded on Nasdaq Stockholm as from 19 January 2026.
Security name:
Alligator Bioscience TO 14
Short name:
ATORX TO 14
ISIN... ► Artikel lesen | |
| 09.01. | Alligator Bioscience to Present New OPTIMIZE-1 Data on Mitazalimab at ASCO Gastrointestinal Cancers Symposium 2026 | 591 | ACCESS Newswire | LUND, SE / ACCESS Newswire / January 9, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced... ► Artikel lesen | |
| 19.12.25 | Alligator Bioscience Announces Preliminary Outcome in Rights Issue | 465 | ACCESS Newswire | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 09.12.25 | Alligator Bioscience Comments on Henlius Receiving Regulatory Approval in China to Initiate Phase 2/3 Trials of HLX22 in HER2-Positive Breast Cancer | 443 | ACCESS Newswire | LUND, SE / ACCESS Newswire / December 9, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that applications for Phase... ► Artikel lesen | |
| 03.12.25 | Alligator Bioscience: Alligator Publishes Supplement Prospectus | 466 | ACCESS Newswire | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 03.12.25 | Listing of units rights and paid subscription units of Alligator Bioscience AB | 301 | GlobeNewswire | With effect from December 04, 2025, the units rights of Alligator Bioscience AB will be traded on the list for Equity rights. Trading will continue up until and including December 15, 2025.
Instrument:
Units... ► Artikel lesen | |
| 03.12.25 | Alligator Bioscience Publishes Financial Calendar for 2026 | 371 | ACCESS Newswire | LUND, SE / ACCESS Newswire / December 3, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX), hereby publishes its financial calendar for 2026:Deadline for Alligator Bioscience's shareholders... ► Artikel lesen | |
| 01.12.25 | Alligator Bioscience Enters into Additional Subscription Undertakings and Top Guarantee Commitments for the Upcoming Rights Issue | 503 | ACCESS Newswire | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA... ► Artikel lesen |
1 2 3 4 Weiter >>
72 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,40 | -0,06 % | BioNTech-Wirkstoff BNT323 zeigt Wirkung bei Gebärmutterkrebs | BioNTech hat positive Daten aus einer Phase-2-Studie mit dem Antikörper-Wirkstoff-Konjugat Trastuzumab Pamirtecan (BNT323/DB-1303) veröffentlicht. In einer Kohorte mit stark vorbehandelten Patientinnen... ► Artikel lesen | |
| EVOTEC | 4,530 | +0,09 % | Evotec-Aktie profitiert von Milliarden-Deal: Gilead kauft Tubulis | Der US-Pharmakonzern Gilead setzt seine Einkaufstour im Biotech-Sektor fort und übernimmt das deutsche Krebsforschungsunternehmen Tubulis für bis zu fünf Milliarden Dollar. Die Transaktion zeigt, wie... ► Artikel lesen | |
| BB BIOTECH | 48,350 | 0,00 % | Dividenden als Portfolio-Anker: Alte Bekannte Sanofi und BB Biotech - Geheimtipp RE Royalties | In einem Marktumfeld, das von strukturellen Umbrüchen geprägt ist, rückt die Stabilität des Portfolios in den Fokus. Analysten von J.P. Morgan betonen, dass der Schutz von Buchgewinnen der vergangenen... ► Artikel lesen | |
| MEDIGENE | 0,025 | -18,83 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| MODERNA | 43,330 | -0,30 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| PAION | 0,051 | -19,84 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 2,668 | -1,11 % | Valneva mit Rekordsignal: Was große Adressen zum Wochenstart bereits wissen - Was erfahrene Anleger jetzt analysieren | ||
| AMGEN | 299,00 | -0,10 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| EPIGENOMICS | 0,920 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 6,860 | -1,01 % | Activist investor revives campaign to overhaul Novavax board | ||
| BIOGEN | 147,04 | -0,28 % | Biogen to acquire Apellis in $5.6bn deal | ||
| BIOFRONTERA | 2,610 | +2,35 % | BIOFRONTERA AG im Abwärtsmodus - ruhige Einordnung | ||
| HEIDELBERG PHARMA | 2,810 | +3,31 % | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Sonstiges
Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest
09.04.2026... ► Artikel lesen | |
| ILLUMINA | 102,88 | -0,23 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen |
Das Unternehmen ALLIGATOR BIOSCIENCE AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,017 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALLIGATOR BIOSCIENCE AB finden Sie auf Wallstreet Online.